Senseibio
1 known investors
Faeth Therapeutics develops oral multi-node inhibitors of the PI3K/AKT/mTOR oncogenic pathway for cancer treatment. The company's lead candidate PIKTOR is an oral combination therapy designed to target multiple pathway nodes simultaneously in endometrial and breast cancer.
BiotechDigital HealthMedical Devices